MX2023002420A - Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas. - Google Patents

Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas.

Info

Publication number
MX2023002420A
MX2023002420A MX2023002420A MX2023002420A MX2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A MX 2023002420 A MX2023002420 A MX 2023002420A
Authority
MX
Mexico
Prior art keywords
methods
embolization
risk
preventing
individual
Prior art date
Application number
MX2023002420A
Other languages
English (en)
Spanish (es)
Inventor
Diana Kerwin
Jason Camm
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of MX2023002420A publication Critical patent/MX2023002420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Steroid Compounds (AREA)
MX2023002420A 2020-08-27 2021-08-27 Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas. MX2023002420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071243P 2020-08-27 2020-08-27
PCT/US2021/048075 WO2022047244A1 (en) 2020-08-27 2021-08-27 Methods for the prevention of cholesterol crystal embolization with cyclodextrins

Publications (1)

Publication Number Publication Date
MX2023002420A true MX2023002420A (es) 2023-07-11

Family

ID=80352440

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002420A MX2023002420A (es) 2020-08-27 2021-08-27 Métodos para la prevención del embolismo por cristales de colesterol con ciclodextrinas.

Country Status (11)

Country Link
US (1) US20230302042A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203973A4 (cg-RX-API-DMAC10.html)
JP (1) JP7895334B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230096976A (cg-RX-API-DMAC10.html)
CN (1) CN116635007A (cg-RX-API-DMAC10.html)
AU (1) AU2021331485A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023003490A2 (cg-RX-API-DMAC10.html)
CA (1) CA3190764A1 (cg-RX-API-DMAC10.html)
IL (1) IL300881A (cg-RX-API-DMAC10.html)
MX (1) MX2023002420A (cg-RX-API-DMAC10.html)
WO (1) WO2022047244A1 (cg-RX-API-DMAC10.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Also Published As

Publication number Publication date
CA3190764A1 (en) 2022-03-03
CN116635007A (zh) 2023-08-22
WO2022047244A1 (en) 2022-03-03
JP2023543132A (ja) 2023-10-13
US20230302042A1 (en) 2023-09-28
EP4203973A4 (en) 2024-08-21
BR112023003490A2 (pt) 2023-05-09
JP7895334B2 (ja) 2026-07-27
AU2021331485A1 (en) 2023-03-23
EP4203973A1 (en) 2023-07-05
KR20230096976A (ko) 2023-06-30
IL300881A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
Fillingham et al. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee society
MX2023002419A (es) Metodos para el tratamiento del embolismo por cristales de colesterol con ciclodextrinas.
Fuji et al. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin
Ker et al. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis
ADEWALE FAWOLE Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban
Konstan Ibuprofen therapy for cystic fibrosis lung disease: revisited
Shinohara et al. II. Cerebral infarction/transient ischemic attack (TIA)
Ryhammer et al. Colloids in cardiac surgery—friend or foe?
Teitel et al. Current status and future prospects for the prophylactic management of hemophilia patients with inhibitor antibodies
Yu et al. Safety and efficacy of tranexamic acid in total knee arthroplasty
Mathews et al. Surgery for hemophilia in developing countries
Jazayeri et al. Reevaluating the role of heparin during mechanical thrombectomy for acute ischemic stroke: Increased risks without functional benefit
BR112023003490A2 (pt) Métodos para prevenção de embolização de cristais de colesterol com ciclodextrinas
Bonarelli et al. Dabigatran etexilate and LMWH for the prevention of venous thromboembolism in 532 patients undergoing hip surgery
Wu et al. Severe chemosis and treatment following fronto-orbital advancement surgery for Crouzon syndrome: a case report
Colwell et al. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery
Rosencher et al. Should new oral anticoagulants replace low-molecular-weight heparin for thromboprophylaxis in orthopaedic surgery?
Psevdos Jr et al. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis
Khemchand et al. Safety, cost effectiveness and experience of day care laparoscopic cholecystectomy: a report from a tertiary care center
Galanis et al. New oral anticoagulants: prevention of VTE in phase III studies in total joint replacement surgery and the hospitalized medically-ill patients
Aledort The ongoing imperative for immune tolerance induction in inhibitor management.
Lyseng-Williamson Nanofiltered human C1 inhibitor concentrate (Cinryze®): A guide to its use in hereditary angioedema in the EU
Lilikakis et al. Thrombocytopenia and intra-cerebral complications associated with low-molecular-weight heparin treatment in patients undergoing total hip replacement: A report of two cases
Tenali MUCORMYCOSIS: ASSESSMENT OF RISK FACTORS IN A SUBJECT SUFFERING FROM CONGENITAL HAEMOPHILIA
Gompou et al. INR deviations in hemodialyzed patients under low dose oral anticoagulant therapy